JA Morgan
JA Morgan
Dana Farber Cancer Institute
Verified email at
Cited by
Cited by
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
GD Demetri, AT van Oosterom, CR Garrett, ME Blackstein, MH Shah, ...
The Lancet 368 (9544), 1329-1338, 2006
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
TF Chu, MA Rupnick, R Kerkela, SM Dallabrida, D Zurakowski, L Nguyen, ...
The Lancet 370 (9604), 2011-2019, 2007
Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors
CP Raut, M Posner, J Desai, JA Morgan, S George, D Zahrieh, ...
Journal of Clinical Oncology 24 (15), 2325-2331, 2006
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors
J Desai, L Yassa, E Marqusee, S George, MC Frates, MH Chen, ...
Annals of internal medicine 145 (9), 660-664, 2006
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
S George, JY Blay, PG Casali, A Le Cesne, P Stephenson, SE Deprimo, ...
European journal of cancer 45 (11), 1959-1968, 2009
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors
AJ Wagner, I Malinowska-Kolodziej, JA Morgan, W Qin, CDM Fletcher, ...
Journal of clinical oncology 28 (5), 835, 2010
Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas
S George, P Merriam, RG Maki, AD Van den Abbeele, JT Yap, T Akhurst, ...
Journal of Clinical Oncology 27 (19), 3154, 2009
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial
S George, Q Wang, MC Heinrich, CL Corless, M Zhu, JE Butrynski, ...
Journal of Clinical Oncology 30 (19), 2401, 2012
Breakpoints of the t (11; 18)(q21; q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18
JA Morgan, Y Yin, AD Borowsky, F Kuo, N Nourmand, JI Koontz, ...
Cancer research 59 (24), 6205-6213, 1999
A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib
TV Patel, JA Morgan, GD Demetri, S George, RG Maki, M Quigley, ...
Journal of the National Cancer Institute 100 (4), 282-284, 2008
Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid TumorsPhase I Study of Everolimus and …
R Quek, Q Wang, JA Morgan, GI Shapiro, JE Butrynski, N Ramaiya, ...
Clinical Cancer Research 17 (4), 871-879, 2011
Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study
E Ben‐Ami, CM Barysauskas, S Solomon, K Tahlil, R Malley, M Hohos, ...
Cancer 123 (17), 3285-3290, 2017
Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors
GD Demetri, P Lo Russo, IRJ MacPherson, D Wang, JA Morgan, ...
Clinical Cancer Research 15 (19), 6232-6240, 2009
Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib FailureSunitinib Treatment …
GD Demetri, MC Heinrich, JA Fletcher, CDM Fletcher, ...
Clinical Cancer Research 15 (18), 5902-5909, 2009
SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic …
GD Demetri, J Desai, JA Fletcher, JA Morgan, CDM Fletcher, ...
Journal of Clinical Oncology 22 (14_suppl), 3001-3001, 2004
Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy
E Choy, JE Butrynski, DC Harmon, JA Morgan, S George, AJ Wagner, ...
BMC cancer 14 (1), 1-6, 2014
Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors
J Desai, S Shankar, MC Heinrich, JA Fletcher, CD Fletcher, J Manola, ...
Clinical Cancer Research 13 (18), 5398-5405, 2007
A phase I–II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors
P Schöffski, P Reichardt, JY Blay, H Dumez, JA Morgan, I Ray-Coquard, ...
Annals of oncology 21 (10), 1990-1998, 2010
Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST)
RG Maki, JA Fletcher, MC Heinrich, JA Morgan, S George, J Desai, ...
Journal of Clinical Oncology 23 (16_suppl), 9011-9011, 2005
Leiomyosarcoma of the inferior vena cava: survival after aggressive management
H Ito, JL Hornick, MM Bertagnolli, S George, JA Morgan, EH Baldini, ...
Annals of surgical oncology 14, 3534-3541, 2007
The system can't perform the operation now. Try again later.
Articles 1–20